Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Desentum

Request full access

Biopharma company in Finland developing allergy vaccines that change the way the immune system reacts to allergens

Espoo, FinlandFounded 2011Biotech & Life Sciences

About Desentum

Desentum is a research-oriented, clinical-stage biopharmaceutical company specialized in developing novel types of allergen immunotherapy products that are based on switching the immune system’s response to allergens from hypersensitivity to tolerance. The goal is to provide long-term relief for patients suffering from allergic symptoms. Desentum’s product development targets both aeroallergens and food allergens.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
76.2/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Vaccines, Allergy, Immune System, Spinout, Biotech and Pharma, Woman Founder, Horizon Europe, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

8 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Apr 2026 $20M $79M Undisclosed ↗
EARLY VCOther financing Feb 2024 $13M $53M Springvest ↗
Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Desentum website traffic

Latest recorded traffic for Desentum is 1.6K monthly website visits, up 122.2% over the last three months. Desentum's team grew 0% over the past year.

Latest monthly visits1.6K 3-month web change+122.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Desentum in the Espoo ecosystem

Live from Dealroom

The Desentum office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • European Commission

Series A3 investors entered at this stage

  • VTT Ventures
  • Cascara ventures
  • Springvest

Other known investors1 additional known investor

  • VTT Technical Research Centre of Finland
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇫🇮 Finland80%
🇳🇱 Netherlands10%
🇸🇪 Sweden10%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Desentum on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Desentum’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.